Helix BioPharma Corp. (HBP.TO)
CAD 1.0
(5.26%)
CAD 1.0
(5.26%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -9.38 Million CAD | -48.5% |
| 2023 | -6.31 Million CAD | 3.97% |
| 2022 | -6.02 Million CAD | 30.67% |
| 2021 | -9.46 Million CAD | -12.32% |
| 2020 | -8.44 Million CAD | -13.8% |
| 2019 | -6.71 Million CAD | 12.04% |
| 2018 | -8.59 Million CAD | 17.24% |
| 2017 | -10.13 Million CAD | -6.52% |
| 2016 | -9.52 Million CAD | -10.58% |
| 2015 | -8.64 Million CAD | -1.51% |
| 2014 | -8 Million CAD | -8.71% |
| 2013 | -7.83 Million CAD | 20.39% |
| 2012 | -17.4 Million CAD | 26.77% |
| 2011 | -12.24 Million CAD | -3.35% |
| 2010 | -13.99 Million CAD | 6.23% |
| 2009 | -13.9 Million CAD | -75.68% |
| 2008 | -7.51 Million CAD | -24.35% |
| 2007 | -7.12 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -1.82 Million CAD | -108.21% |
| 2024 Q1 | -1.23 Million CAD | 41.57% |
| 2024 Q4 | -5.3 Million CAD | -190.25% |
| 2024 Q2 | -899 Thousand CAD | 29.73% |
| 2023 Q2 | -1.21 Million CAD | 22.58% |
| 2023 Q1 | -1.57 Million CAD | -13.75% |
| 2023 FY | - CAD | 3.97% |
| 2023 Q4 | -2.13 Million CAD | -59.07% |
| 2023 Q3 | -1.33 Million CAD | -10.02% |
| 2022 Q4 | -1.38 Million CAD | -2.29% |
| 2022 Q3 | -1.35 Million CAD | 31.8% |
| 2022 Q2 | -1.98 Million CAD | -9.45% |
| 2022 Q1 | -1.81 Million CAD | 32.34% |
| 2022 FY | - CAD | 30.67% |
| 2021 Q4 | -2.67 Million CAD | -5.15% |
| 2021 FY | - CAD | -12.32% |
| 2021 Q3 | -2.54 Million CAD | -35.1% |
| 2021 Q2 | -1.88 Million CAD | 18.48% |
| 2021 Q1 | -2.31 Million CAD | -24.66% |
| 2020 Q4 | -1.85 Million CAD | 22.11% |
| 2020 FY | - CAD | -13.8% |
| 2020 Q1 | -2.17 Million CAD | -0.79% |
| 2020 Q2 | -2.2 Million CAD | -1.06% |
| 2020 Q3 | -2.37 Million CAD | -8.14% |
| 2019 Q3 | -2.02 Million CAD | -10.2% |
| 2019 Q2 | -1.83 Million CAD | -35.68% |
| 2019 Q1 | -1.35 Million CAD | 12.61% |
| 2019 FY | - CAD | 12.04% |
| 2019 Q4 | -2.16 Million CAD | -6.93% |
| 2018 Q4 | -1.54 Million CAD | 26.21% |
| 2018 FY | - CAD | 17.24% |
| 2018 Q3 | -2.09 Million CAD | 16.33% |
| 2018 Q2 | -2.5 Million CAD | -12.49% |
| 2018 Q1 | -2.22 Million CAD | -72.69% |
| 2017 Q1 | -3.23 Million CAD | -26.06% |
| 2017 FY | - CAD | -6.52% |
| 2017 Q4 | -1.28 Million CAD | 54.85% |
| 2017 Q3 | -2.85 Million CAD | -4.58% |
| 2017 Q2 | -2.73 Million CAD | 15.64% |
| 2016 Q1 | -2.55 Million CAD | -22.94% |
| 2016 Q2 | -2.16 Million CAD | 15.21% |
| 2016 FY | - CAD | -10.58% |
| 2016 Q4 | -2.56 Million CAD | -15.84% |
| 2016 Q3 | -2.21 Million CAD | -2.45% |
| 2015 FY | - CAD | -1.51% |
| 2015 Q4 | -2.07 Million CAD | -11.74% |
| 2015 Q3 | -1.85 Million CAD | 27.97% |
| 2015 Q2 | -2.57 Million CAD | -24.0% |
| 2015 Q1 | -2.07 Million CAD | -21.15% |
| 2014 Q1 | -2.09 Million CAD | -17.5% |
| 2014 Q3 | -2.05 Million CAD | 20.85% |
| 2014 Q4 | -1.71 Million CAD | 16.46% |
| 2014 Q2 | -2.59 Million CAD | -23.87% |
| 2014 FY | - CAD | -8.71% |
| 2013 Q1 | -1.93 Million CAD | 75.38% |
| 2013 FY | - CAD | 20.39% |
| 2013 Q2 | -1.64 Million CAD | 15.08% |
| 2013 Q4 | -1.78 Million CAD | 14.93% |
| 2013 Q3 | -2.09 Million CAD | -27.49% |
| 2012 Q3 | -2.59 Million CAD | 71.86% |
| 2012 Q4 | -7.86 Million CAD | -202.5% |
| 2012 FY | - CAD | 26.77% |
| 2012 Q2 | -9.23 Million CAD | -197.14% |
| 2012 Q1 | -3.1 Million CAD | 19.17% |
| 2011 Q4 | -3.84 Million CAD | -34.72% |
| 2011 FY | - CAD | -3.35% |
| 2011 Q1 | -3.66 Million CAD | 0.0% |
| 2011 Q2 | -3.64 Million CAD | 0.38% |
| 2011 Q3 | -2.85 Million CAD | 21.74% |
| 2010 FY | - CAD | 6.23% |
| 2009 FY | - CAD | -75.68% |
| 2008 FY | - CAD | -24.35% |
| 2007 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Appili Therapeutics Inc. | -2.09 Million CAD | -347.868% |
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | 74.893% |
| Microbix Biosystems Inc. | 1.95 Million CAD | 579.749% |
| Medicenna Therapeutics Corp. | -18.67 Million CAD | 49.711% |
| Satellos Bioscience Inc. | -15.7 Million CAD | 40.216% |
| Oncolytics Biotech Inc. | -33.71 Million CAD | 72.148% |
| Sernova Corp. | -40.19 Million CAD | 76.64% |